Zoetis Inc., one of the drug manufacturers to receive conditional regulatory approval to market vaccines for porcine epidemic diarrhea virus, is "seeking proposals for well-defined studies that focus on optimizing the immune response of sows and gilts for the control of PEDV," says a press release from the company. A total of $125,000 in grants will be awarded by Zoetis for studies that provide insights into new methods that can help control PEDV in breeding and farrowing herds. The virus has been reported in 31 states and has killed millions of pigs. (Wall Street Journal graphic)
Research must be conducted in the U.S., and proposals need to be submitted by Dec. 5, says Zoetis. "To receive a copy of the abstract template or to submit questions, email PEDvResearch@zoetis.com. A committee will review the proposals, and an announcement of the successful applications will be made in January." (Read more)
No comments:
Post a Comment